BHVN Inventory Rockets: Pfizer Snaps Up Biohaven For Almost $12 Billion

Pfizer (PFE) will purchase migraine drugmaker Biohaven Prescribed drugs (BHVN) for practically $12 billion in a deal “that could not have come at a greater time,” based on one analyst. The information despatched BHVN inventory rocketing.

X

The takeover marries Biohaven’s efforts in migraine remedy with Pfizer’s presence within the major care house, Wedbush analyst Laura Chico stated in a report back to shoppers. Biohaven’s drug, Nurtec, blocks a peptide referred to as CGRP to deal with and forestall migraines. Pfizer already owns the abroad rights to Nurtec.

Non-CGRP belongings will likely be spun out into their very own firm known as “New Biohaven.”

“(The deal) could not have come at a greater time,” Chico stated. “Given Pfizer’s presence within the major care house and current neurology franchise, we see the CGRP portfolio becoming in properly.”

In early buying and selling on today’s stock market, BHVN inventory rocketed 70.6% close to 141.80. Pfizer stock rose 1.6% close to 49.40.

BHVN Inventory: Pfizer Pays Hefty Premium

Pfizer pays $148.50 per share of BHVN inventory and settle Biohaven’s third-party debt. The phrases worth Biohaven inventory at a 33% premium to the common volume-weighted worth of 111.70 over the previous three months. Traders may also obtain half a share of the “New Biohaven.”

Biohaven additionally introduced its first-quarter report which included $124 million in Nurtec gross sales. That was effectively beneath analysts’ name for $181 million, Wedbush’s Chico stated. However the firm expects $825 million to $900 million in full-year gross sales which “implies an acceleration in development” in late 2022.

Chico saved her outperform ranking on BHVN inventory.

The cope with Pfizer additionally consists of experimental migraine medicine rimegepant and zavegepant in addition to 5 preclinical CGRP belongings.

“Whereas takeout has lengthy been rumored as a possible end result, we see this deal making sense in each phrases of the suitor and the timing,” Chico went on to say. “We do not need to dismiss the potential of a competing bid to emerge, nonetheless, the Pfizer bid seems honest and full.”

Mild First-Quarter Nurtec Gross sales

Mizuho Securities analyst Vamil Divan would not count on every other suitors to emerge.

“We consider different massive gamers within the migraine house both have already got acute migraine medicine of their portfolio, or will not be able to do an acquisition of this dimension,” he stated in his word to shoppers. “We additionally don’t see any main upcoming occasions that may probably influence the deal.”

He has a purchase ranking on BHVN inventory and holds a impartial ranking on Pfizer shares.

Like Wedbush’s Chico, Divan famous the first-quarter Nurtec gross sales quantity lagged expectations. However gross sales have been probably snagged on first-quarter payer dynamics throughout the migraine house, additionally impacting AbbVie (ABBV), he stated.

These dynamics “ought to normalize over the course of the complete yr and over the long run,” he stated.

Comply with Allison Gatlin on Twitter at @IBD_AGatlin.

YOU MAY ALSO LIKE:

IBD Stock Of The Day Merck Notches Quarterly Beat As Covid Pill Brings In $3.2 Billion

Eli Lilly Extends Its Breakout On First-Quarter Beat, Bullish News In Obesity

IBD Stock Of The Day: See How To Find, Track And Buy The Best Stocks

Watch IBD’s Investing Strategies Show For Actionable Market Insights

IBD Digital: Unlock IBD’s Premium Stock Lists, Tools And Analysis Today